Repligen (NASDAQ:RGEN) Now Covered by Analysts at Guggenheim

Guggenheim started coverage on shares of Repligen (NASDAQ:RGEN) in a research note released on Tuesday, MarketBeat reports. The brokerage issued a neutral rating on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a research report on Thursday, February 22nd. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $230.00 to $200.00 and set an overweight rating for the company in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $197.75.

Repligen Stock Up 4.4 %

Shares of Repligen stock opened at $125.32 on Tuesday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $155.29 and a 200 day moving average price of $175.02. The stock has a market cap of $7.00 billion, a price-to-earnings ratio of 501.30, a price-to-earnings-growth ratio of 4.11 and a beta of 1.04. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 earnings per share. Equities research analysts forecast that Repligen will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Martin D. Madaus acquired 1,615 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the purchase, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. YHB Investment Advisors Inc. acquired a new stake in shares of Repligen in the first quarter valued at approximately $26,000. Lazard Asset Management LLC increased its stake in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the period. Principal Securities Inc. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $48,000. Finally, CWM LLC increased its stake in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.